MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
10.53
+0.01
+0.10%
Pre Market: 10.37 -0.16 -1.52% 05:04 04/01 EDT
OPEN
10.58
PREV CLOSE
10.52
HIGH
11.05
LOW
9.97
VOLUME
12
TURNOVER
50.06K
52 WEEK HIGH
76.00
52 WEEK LOW
6.34
MARKET CAP
49.43M
P/E (TTM)
-3.4706
1D
5D
1M
3M
1Y
5Y
1D
MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
TipRanks · 2h ago
MiNK Therapeutics’ Earnings Call Signals High-Risk Upside
TipRanks · 12h ago
MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026
Seeking Alpha · 22h ago
MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12
Seeking Alpha · 1d ago
MiNK Therapeutics Reports Progress in New Treatments for Lung Disease, Cancer and Immune Disorders
Benzinga · 1d ago
*MiNK Therapeutics 4Q Loss $2.6M >INKT
Dow Jones · 1d ago
*MiNK Therapeutics 4Q Loss/Shr 56c >INKT
Dow Jones · 1d ago
Press Release: MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
Dow Jones · 1d ago
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.